Ones To Watch News
Refine search
Biotechnology
US biotech Prolium Bioscience has announced its launch with a $50 million Series A financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. 4 March 2026
Biotechnology
US biotechnology company Candid Therapeutics will go public through a reverse merger with US rare disease drugmaker Rallybio, creating a Nasdaq-listed company focused on T-cell engager therapies for autoimmune diseases. 4 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Pharmaceutical
US clinical-stage biotech Latigo Biotherapeutics has appointed Neha Krishnamohan as chief financial officer and chief business officer, adding a finance executive with experience across biotech capital markets and corporate strategy as the company advances its non-opioid pain pipeline. 4 March 2026
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into an agreement to expand the drug discovery collaboration agreement with Canada’s Congruence Therapeutics for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. 4 March 2026
Biotechnology
Belgium’s largest drugmaker UCB and Hong Kong based biotech Antengene have entered into an agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201 and access to its associated manufacturing technology in relation to ATG-201. Antengene’s shares rose almost 10% to HK$3.16 on the news. 4 March 2026
Pharmaceutical
Priovant Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. 3 March 2026
Biotechnology
UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer. 3 March 2026
Biotechnology
US biotech Generate Biomedicines raised $400 million in its initial public offering, selling 25 million shares at $16 each, the midpoint of its range. It marks the largest biotech IPO so far this year and signals a tentative reopening of the sector’s capital markets. 2 March 2026
Biotechnology
Netherlands-based immunology company argenx has announced positive topline results from the Phase III ADAPT OCULUS study of Vyvgart (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG). 1 March 2026
Pharmaceutical
Switzerland’s Santhera Pharmaceuticals has announced that the Spanish Interministerial Commission on Prices of Medicines has proposed to include Agamree (vamorolone) in the pharmaceutical coverage of the National Health System, making it eligible for reimbursement. 27 February 2026
Pharmaceutical
Atrium Therapeutics launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. 27 February 2026
Biotechnology
German family-owned pharma major Boehringer Ingelheim and UK clinical stage biotech Sitryx Therapeutics announced that Boehringer has acquired an exclusive license for a pre-clinical, small molecule program from Sitryx. 27 February 2026
Pharmaceutical
UK-Hungarian virtual biology company Turbine has secured $25 million in a series B financing, broadened its platform beyond oncology and struck a new immunology collaboration with a top 10 pharma group. 26 February 2026
Biotechnology
Douglas Ingram has told Sarepta Therapeutics of his decision to retire as chief executive of the US genetic medicines company by the end of 2026 or upon the appointment of his replacement. 26 February 2026
Biotechnology
Privately-held US firm Abcuro has announced topline results from the Phase II/III MUSCLE study of ulviprubart (ABC008). 25 February 2026
Biotechnology
US biotech Generate Biomedicines has set terms for a proposed Nasdaq listing that could raise up to $425 million, as it moves to finance two Phase III asthma trials for its lead antibody. The company plans to offer 25 million shares at $15 to $17 each. 25 February 2026
Biotechnology
US biotech Slate Medicines has launched with $130 million in series A funding to advance an experimental migraine antibody licensed from China-based DartsBio Pharmaceuticals into the clinic next year. 25 February 2026
Pharmaceutical
The days of flying under the radar are over for Isotope Technologies Munich (ITM), a privately-held German radiopharmaceutical company. 25 February 2026
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has announced topline results from the S-OLARIS Phase II trial. 24 February 2026
Biotechnology
Belgium’s largest pharma company UCB announced that it has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. 18 April 2026
Biotechnology
For most of oncology’s history, the fight against cancer has begun once the disease is diagnosed. UK-based Athernal Bio is building its platform around an earlier and potentially more powerful point of intervention: addressing biological changes in the body that accumulate silently before cancer develops. 17 April 2026
Pharmaceutical
Recently-launched US obesity company Kailera Therapeutics has announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. 17 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
California-based liver and viral disease specialist Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection, the company announced yesterday. 17 April 2026
Biotechnology
Genetic medicines company MeiraGTx Holdings has reacquired global rights to its Phase III gene therapy candidate for X-linked retinitis pigmentosa (XLRP), botaretigene sparoparvovec (bota-vec), from Johnson & Johnson, and priced a $100 million public offering of ordinary shares to support advancement of its late-stage pipeline. 16 April 2026
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze